PACS Insiders Sold $31M Before Q2 Beat, Guidance Lift
PACS Group reported Q2 adjusted EPS of $0.63, beating consensus by 17%, with net income up 50% year-over-year and full-year adjusted EBITDA guidance raised to $640M-$660M. In the six weeks before that
PACS Insiders Sold $31M Before Q2 Beat, Guidance Lift
NEW YORK, August 6 —
PACS Group, Inc. (PACS) reported Q2 adjusted EPS of $0.63, beating the FactSet consensus of $0.54 by 17%, as net income rose 50% year-over-year, while co-founder Mark Hancock and two other officers sold a combined $31 million in shares in the six weeks before that result was announced, starting at prices as low as $35.28.
- Q2 adjusted EPS $0.63 vs. $0.54 estimate; net income $76.4M, up 50% year-over-year. [earnings call]
- Full-year adjusted EBITDA guidance raised to $640M, $660M; revenue guidance $5.75B, $5.85B. [earnings call]
- $31M in insider sales across three officers over 90 days; zero purchases filed. [Form 4s]
The Quarter Itself Was Strong
PACS Group operates 324 skilled nursing, assisted living, and senior care facilities across the United States, 35,631 beds in total, and Q2 showed the operating model working as designed. Revenue reached $1.43 billion, up 9.1% year-over-year, while cost of services grew only 6.7%; the spread pushed adjusted EBITDA margin 150 basis points higher to 11.7%. Same-store skilled nursing occupancy rose to 90.6% and skilled patient mix, the higher-reimbursement category that management calls the primary per-bed revenue driver, ticked up 100 basis points to 30%. High CMS star ratings build referral partner trust, management says, which supports both occupancy and skilled mix. The quarter delivered adjusted EBITDA of $166.8 million, up 25% year-over-year, and a guidance raise. On those numbers, the story is straightforward execution.
The Selling Pattern
The Form 4 record tells a different story about insider conviction. Co-founder and Executive Vice Chair Mark Hancock began selling on June 15, weeks before the Q2 results were public, disposing of 134,093 shares at $36.23 and 19,138 shares at $37.05 that day alone, per filings. He continued through June 16-17, then again on June 25-26 at $40.33, $40.50, then through July 1-6 at approximately $45, culminating in a single 142,163-share sale for roughly $6.44 million on July 6. President & COO Joshua Jergensen sold approximately $1.8 million on July 15. Chief Accounting Officer Michelle Renee Lewis sold across four separate dates from June 25 through July 6. In aggregate: $31 million out the door, zero shares purchased, across three insiders spanning six weeks straddling the quarter-end.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| PACS | $7.2B | 18.7x | +302.7% |
| BTSG | $12.5B | 27.7x | +195.0% |
| SEZL | $5.9B | 26.7x | +14.5% |
| ULS | $16.0B | 30.4x | +39.2% |
| LOAR | $7.1B | 48.1x | +1.9% |
| ALMS | $3.5B | n/a | +497.7% |
What to Watch Next Quarter
The data alone doesn't settle the question. Insiders sell for many reasons, diversification, estate planning, tax management, and PACS's 106 facilities still in the "ramping" phase represent a genuine organic growth runway that management is actively funding: $190.8 million in real estate investment in the first half of 2026 alone, against net leverage of just 0.1 times and $756.6 million in available liquidity. Q3 will show whether occupancy, skilled mix, and margin hold at the pace the raised guidance implies, or whether the pre-announcement selling reflected a view of the business the published numbers have yet to confirm. The specific figure to watch: whether same-store skilled nursing occupancy holds above 90% and skilled patient mix sustains the 30% threshold. Run the free PACS Group, Inc. deep-dive →
Current fundamentals, valuation and filing history for PACS Group, Inc. (PACS) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
How much did PACS Group insiders sell before earnings?
Three officers sold a combined $31 million in shares over a six-week window straddling the quarter-end, with zero shares purchased. Co-founder Mark Hancock was the largest seller, beginning on June 15, weeks before Q2 results were announced. President Joshua Jergensen and Chief Accounting Officer Michelle Renee Lewis also filed sales across the same period.
What were PACS Group Q2 2026 earnings results?
PACS Group reported Q2 adjusted EPS of $0.63, beating the FactSet consensus of $0.54 by 17%, while net income rose 50% year-over-year to $76.4 million. Revenue reached $1.43 billion, up 9.1% year-over-year, and adjusted EBITDA came in at $166.8 million, up 25% year-over-year.
Did PACS Group raise full-year guidance?
Yes. Following Q2 results, management raised full-year adjusted EBITDA guidance to $640M-$660M and revenue guidance to $5.75B-$5.85B. Adjusted EBITDA margin also expanded 150 basis points to 11.7% in the quarter.
What is PACS Group's skilled nursing occupancy rate?
Same-store skilled nursing occupancy rose to 90.6% in Q2, while skilled patient mix increased 100 basis points to 30%. Management attributes the improvement to a cycle in which high CMS star ratings build referral partner trust, supporting both occupancy and the higher-reimbursement patient category.
Why do PACS insiders sell shares before earnings?
The article notes that insiders sell for many reasons, including diversification, estate planning, and tax management, and the available data does not resolve the tension with the strong Q2 result. The specific figures to watch in Q3 are whether same-store skilled nursing occupancy holds above 90% and skilled patient mix sustains the 30% threshold.
PACS Group posted Q2 adjusted EPS of $0.63, beating the FactSet consensus of $0.54 by 17%, and raised its full-year adjusted EBITDA guidance to $640M–$660M — while co-founder Mark Hancock and two other insiders sold a combined $31M in shares in the six weeks before the report, beginning at prices as low as $35.28.